FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2069884075> ?p ?o ?g. }

• W2069884075 abstract "Neurocognitive changes were observed in a pilot study with Alzheimer's disease (AD) patients submitted to plasma exchanges (PE) with Grifols 5% albumin (Albutein®) suggesting that further study is required to evaluate this treatment as a novel approach. Thirty-nine patients with mild-moderate AD receiving stable donepezil treatment were randomized to 2 groups (1:1): a control group and a treatment group. Both groups received a maximum of 18 PE with three different PE schedules with 5% Albutein®: 2 PE/week for 3 weeks, 1 PE/week for 6 weeks and 1 PE/2 weeks for 12 weeks. After the treatment period, there was a 6 months follow-up period for both groups. The control group followed the same program, except that the PE was a sham procedure. Plasma and CSF Aβ40 and Aβ42 levels, neuropsychological scores (MMSE, ADAS-Cog) and neuroimaging (MRI and SPECT) were performed along the study. The study was designed as a multicenter, randomized, blind, controlled, parallel-group, phase II study. In the treatment group treated patients, plasma Aβ40 levels showed consistent variations in the form of a saw-tooth pattern throughout the three PE periods, replicating findings previously observed in the pilot study. After the PE periods, plasma Aβ40 levels returned to baseline. Furthermore, treated patients scored better than control patients in cognitive evaluation (differences between groups at 9 months: 2.2 in MMSE and 4.5 in ADAS-Cog) but worsened at 12 months of follow-up (6 months after PE was over). Neuroimaging results have been reported in another abstract submitted to this congress by the same group. No plasma Aβ40 variations were observed in the control group. These results confirm those of the pilot study suggesting that PE with Grifols 5% Albutein® consistently mobilizes plasma Aβ levels. This type of mobilization was also observed for Grifols intravenous immunoglobulin (Flebogamma® DIF) suggesting that a combined treatment of plasmapheresis with 5% Albutein® and Flebogamma® DIF might be justified when a synergic effect is sought. However, the differences observed in cognitive scores need further confirmation in larger clinical trials." @default.
• W2069884075 created "2016-06-24" @default.
• W2069884075 creator A5000720441 @default.
• W2069884075 creator A5001416778 @default.
• W2069884075 creator A5012153894 @default.
• W2069884075 creator A5028233317 @default.
• W2069884075 creator A5034302542 @default.
• W2069884075 creator A5037969626 @default.
• W2069884075 creator A5046635335 @default.
• W2069884075 creator A5046904387 @default.
• W2069884075 creator A5052552899 @default.
• W2069884075 creator A5054471387 @default.
• W2069884075 creator A5057731725 @default.
• W2069884075 creator A5059526712 @default.
• W2069884075 creator A5060103925 @default.
• W2069884075 creator A5072218413 @default.
• W2069884075 creator A5079557074 @default.
• W2069884075 creator A5083375508 @default.
• W2069884075 creator A5087229615 @default.
• W2069884075 date "2012-07-01" @default.
• W2069884075 modified "2023-10-17" @default.
• W2069884075 title "P1-337: Results of a phase II study of plasma exchange with 5 percent albumin (Albutein®) in Alzheimer's disease patients" @default.
• W2069884075 doi "https://doi.org/10.1016/j.jalz.2012.05.2023" @default.
• W2069884075 hasPublicationYear "2012" @default.
• W2069884075 type Work @default.
• W2069884075 sameAs 2069884075 @default.
• W2069884075 citedByCount "0" @default.
• W2069884075 crossrefType "journal-article" @default.
• W2069884075 hasAuthorship W2069884075A5000720441 @default.
• W2069884075 hasAuthorship W2069884075A5001416778 @default.
• W2069884075 hasAuthorship W2069884075A5012153894 @default.
• W2069884075 hasAuthorship W2069884075A5028233317 @default.
• W2069884075 hasAuthorship W2069884075A5034302542 @default.
• W2069884075 hasAuthorship W2069884075A5037969626 @default.
• W2069884075 hasAuthorship W2069884075A5046635335 @default.
• W2069884075 hasAuthorship W2069884075A5046904387 @default.
• W2069884075 hasAuthorship W2069884075A5052552899 @default.
• W2069884075 hasAuthorship W2069884075A5054471387 @default.
• W2069884075 hasAuthorship W2069884075A5057731725 @default.
• W2069884075 hasAuthorship W2069884075A5059526712 @default.
• W2069884075 hasAuthorship W2069884075A5060103925 @default.
• W2069884075 hasAuthorship W2069884075A5072218413 @default.
• W2069884075 hasAuthorship W2069884075A5079557074 @default.
• W2069884075 hasAuthorship W2069884075A5083375508 @default.
• W2069884075 hasAuthorship W2069884075A5087229615 @default.
• W2069884075 hasConcept C118552586 @default.
• W2069884075 hasConcept C126322002 @default.
• W2069884075 hasConcept C14216870 @default.
• W2069884075 hasConcept C168563851 @default.
• W2069884075 hasConcept C169900460 @default.
• W2069884075 hasConcept C172467417 @default.
• W2069884075 hasConcept C2776125364 @default.
• W2069884075 hasConcept C71924100 @default.
• W2069884075 hasConcept C90924648 @default.
• W2069884075 hasConceptScore W2069884075C118552586 @default.
• W2069884075 hasConceptScore W2069884075C126322002 @default.
• W2069884075 hasConceptScore W2069884075C14216870 @default.
• W2069884075 hasConceptScore W2069884075C168563851 @default.
• W2069884075 hasConceptScore W2069884075C169900460 @default.
• W2069884075 hasConceptScore W2069884075C172467417 @default.
• W2069884075 hasConceptScore W2069884075C2776125364 @default.
• W2069884075 hasConceptScore W2069884075C71924100 @default.
• W2069884075 hasConceptScore W2069884075C90924648 @default.
• W2069884075 hasIssue "4S_Part_6" @default.
• W2069884075 hasLocation W20698840751 @default.
• W2069884075 hasOpenAccess W2069884075 @default.
• W2069884075 hasPrimaryLocation W20698840751 @default.
• W2069884075 hasRelatedWork W2015902346 @default.
• W2069884075 hasRelatedWork W2018327468 @default.
• W2069884075 hasRelatedWork W2065294369 @default.
• W2069884075 hasRelatedWork W2165218645 @default.
• W2069884075 hasRelatedWork W2501687141 @default.
• W2069884075 hasRelatedWork W2746475541 @default.
• W2069884075 hasRelatedWork W34490740 @default.
• W2069884075 hasRelatedWork W4253315271 @default.
• W2069884075 hasRelatedWork W4256514411 @default.
• W2069884075 hasRelatedWork W3028761177 @default.
• W2069884075 hasVolume "8" @default.
• W2069884075 isParatext "false" @default.
• W2069884075 isRetracted "false" @default.
• W2069884075 magId "2069884075" @default.
• W2069884075 workType "article" @default.